查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1847924

RNA分析/转录组学市场（按产品、技术和应用）—全球预测 2025-2032

RNA Analysis/Transcriptomics Market by Product, Technology, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

RNA 分析/转录组学市场预计到 2032 年将成长到 134.6 亿美元，复合年增长率为 10.79%。

主要市场统计数据
基准年2024年 59.2亿美元
预计2025年 65.7亿美元
预测年份：2032年 134.6亿美元
复合年增长率（%） 10.79%

全面介绍在研究和临床环境中影响 RNA 分析和转录组学的科学、操作和转化力量

RNA分析和转录组学领域正处于关键的十字路口，在分子生物学、定序技术和计算分析技术的推动下，它们正在重新定义实验和临床方法。在过去几年中，该领域已超越简单的基因表现到为药物开发、诊断和精密农业提供资讯的转化应用。因此，研究和商业实验室现在优先考虑整合的工作流程，以缩短从样本到洞察的时间，同时提高可重复性和资料互通性。

在这种动态中，实验室领导者和策略规划人员必须平衡对重复性耗材、固定设备和软体支援分析的投资。营运决策越来越取决于能否将湿实验室通讯协定与强大的生物资讯流程（包括支援大型转录组学资料集的云端原生解决方案）相协调。此外，相关人员的期望也在改变：资助者和监管机构要求透明的检验，临床合作伙伴要求标准化的检测方法，而出版机构则要求全面的元资料和可重复的流程。总而言之，RNA分析领域正在奖励那些将卓越的技术与严谨的营运、全面的数据管理以及清晰的转换蓝图相结合以连接发现和应用的机构。

高通量测序、单细胞创新和软体主导的生态系统的融合如何重新定义转录组学的营运重点和商业模式

转录组学领域正在经历一场变革性的转变，这不仅反映了技术的成熟度，也反映了终端使用者需求的变化。从技术角度来看，定序通量的提高和每个样本处理时间的缩短，使得单细胞方法和高内涵批量研究得以广泛应用，促使实验室重新思考实验设计，以便对生物系统进行更深入、更细緻的研究。同时，数位PCR和改进的即时PCR方法继续为靶向检测提供快速、灵敏的选择，支援需要在基因组范围内进行定量准确性的诊断和验证工作流程。

同样重要的是实验室自动化、新型微流体平台和机器学习主导的分析的融合，它们共同实现了更高的吞吐量和更可重复的数据生成。这种整合正在将价值从独立仪器转移到耦合的生态系统，其中耗材、仪器韧体和分析软体共同优化。经营模式正在相应调整。以订阅和服务为中心的软体和云端分析方法正变得越来越突出，而製造商则优先考虑针对临床和法规环境的经过验证的端到端解决方案。此外，随着协力网路和多站点研究的扩展，资料交换、品管和检测检验的标准变得越来越重要，从而创造了一个互通性和合规性作为关键竞争优势的环境。

评估近期美国关税行动对转录组学全球采购、供应弹性和平台选择的累积营运和策略影响

美国近期的贸易政策发展和关税行动导致全球RNA分析所需的实验室设备、试剂及相关组件的供应链重新调整。依赖跨国采购的公司和机构经历了筹资策略的转变，扩大了供应商资格认证流程，并更加重视库存弹性。关税相关的成本压力促使製造商评估替代采购、本地化某些生产过程，并重新协商供应商合同，以维持净利率并确保供应的连续性。

在营运方面，这些变更表现前置作业时间延长，采购团队设立了紧急库存和多样化的供应商清单，以减少中断。研究小组调整了采购顺序，以减少与进口相关的延误风险，在某些情况下，他们选择了本地服务覆盖范围更广的平台。从产品开发的角度来看，正在加速推进可製造设计，以减少对地缘政治敏感部件的依赖，并实现跨地区的模组化采购。

此外，关税的累积影响正在推动供应商和经销商之间建立策略伙伴关係，以促进海关合规并简化物流流程。这些合作通常包括对区域仓库的共同投资、统一的文件流程以及扩展的现场服务网路。对于转化研究和临床测试部署而言，最终效果是更加重视供应链透明度、供应商管理和合约保障，从而协调采购和营运风险接受度。展望未来，相关人员可能会继续优先考虑采购决策的韧性和灵活性，同时密切关注可能改变关键临床测试投入跨境贸易动态的政策变化。

深度細項分析，说明不同的产品、技术和应用途径如何在转录组学工作流程中产生差异化的需求讯号和研发重点

细緻的细分观点揭示了RNA分析中每种产品、技术和应用的独特需求驱动因素和采用障碍。按产品类型划分，对耗材和试剂的持续需求支撑着实验室的连续性，对于需要稳定批间性能和可靠供应的最终用户而言，这仍然是核心营运重点。仪器仍然是资本配置决策的关键，因为平台选择会影响通量、检测相容性和下游资料特性。互补的软体和服务构成了将原始测量数据转化为可操作知识的纽带，从而支持标准化、合规性和多中心研究的可扩展分析。

从技术角度来看，该生态系统包括数位PCR和即时PCR，它们是用于标靶定量和检验的强大工具，而微阵列技术则在特定的比较表达研究中占据一席之地。次世代定序仪已成为主流的高解析度方法，批量转录组学可满足广泛的发现用例，而单细胞转录组学则能够研究异质组织和稀有细胞类型。同时，基于微流体的平台可为专门的侦测和多组体学整合提供精确控制。每种技术类别都有不同的样品製备要求、计算需求和品管基准，从而影响各组织之间的采用曲线。

应用主导的细分进一步明确了优先顺序。癌症研究持续需要深度转录组分析来阐明肿瘤异质性和治疗抗药性机制，而药物研发则利用表达特征和通路分析来识别标靶并进行动态。基因检测项目需要涵盖携带者筛检、疾病诊断以及产前和新生儿应用的强大且经过验证的检测方法，尤其註重检测方法的灵敏度、特异性和监管准备度。感染疾病研究需要快速、灵敏的检测方法和可扩展的定序来追踪病原体和宿主的反应，而植物研究也越来越多地采用转录组工具来加速性状发现和压力反应表征。了解这些相互交叉的细分轴，使公司能够根据每个用户群体的细微需求自订产品系列、研发投资和商业策略。

区域动态和基础设施现实将影响世界不同地区的转录组学采用途径、伙伴关係策略和监管协调

区域动态反映了研究资金、监管格局、产业环境和临床基础设施的差异，决定了转录组学工具和服务的采用、支持和商业化方式。在美洲，由学术中心、生物技术公司和临床实验室组成的密集生态系统正在推动先进定序平台和单细胞技术的早期应用，转化研究与商业性创新之间有着密切的联繫。这种环境催生了一个竞争激烈的服务供应商领域，支援快速技术检验、策略联盟以及从发现到临床级检测的规模化扩展。

欧洲、中东和非洲地区的采用模式各不相同。主要的卓越中心和国家级倡议加速了高通量平台和标准化工作流程的采用，而更广泛的地区差异则反映了资金和实验室基础设施取得的差异。欧洲法律规范特别强调临床验证和资料隐私，供应商则强调合规性和在地化支援。同时，合作联盟和广泛地区计划有助于传播最佳实践，并实现高成本技术的资源共用。

在亚太地区，公共和私人对生命科学的投资不断增长，推动了对设备和耗材的需求。新兴经济体正在发展国内製造和服务能力，这影响了采购偏好和价格敏感度。研究机构和临床基因组学计画的快速发展，推动了製药、农业和公共卫生领域的应用。这些区域动态的结合需要差异化的商业策略。跨国供应商必须根据当地的监管要求、基础设施成熟度和客户支援期望，客製化其市场进入方式、服务模式和伙伴关係。

解决方案供应商之间的竞争行为、整合策略和能力优先顺序决定了转录组学领域的供应商选择和伙伴关係机会

RNA分析和转录组学价值链上的公司活动体现了技术差异化、服务扩展和策略整合的融合。仪器製造商持续在通量、准确性和易用性方面竞争，而试剂製造商则强调稳健的化学过程、批次一致性和经过验证的工作流程，以降低检验的差异性。同时，分析服务供应商和软体供应商正在加速对云端原生平台、标准化流程和解释层的投资，以满足研究和临床报告的需求。

策略行动包括有针对性的併购，以确保专有的化学和分析资产；基于伙伴关係关係的上市方式，将仪器与耗材和资讯服务捆绑在一起；以及扩展现场服务网络以支持全球扩张。成功整合硬体、化学和软体的公司通常能够透过减轻最终用户的检验负担并加快洞察时间而获得竞争优势。相反，专注于利基分析化学、微流体创新和先进生物资讯学的专业供应商可以透过与平台供应商和受託研究机构的合作来获取价值。

对于客户而言，供应商选择如今包括评估长期支援、互通性以及检验应用的广度。采购决策也越来越多地考虑蓝图透明度、监管准备以及培训和应用支援的可用性。不断变化的竞争格局有利于那些能够展示可重复性、全面的检验资料集以及在产业中实现临床转化和规模化推广的实用途径的组织。

领导者建构弹性供应链、可互通的生态系统和临床适用的转录组学产品的策略要务

产业领导者应采取积极主动的立场，强调其产品和业务组合的弹性、互通性和转化准备度。首先，组织蓝图必须优先考虑湿实验室团队、生物资讯部门和采购部门之间的跨职能协作，以确保平台选择既能带来即时的实验效益，又能实现长期的可扩展性。投资决策应优先考虑模组化解决方案，这些解决方案能够实现增量容量扩展，并在不牺牲检验效能的情况下最大限度地减少对专有组件的锁定。

其次，企业应注重供应链透明度和多元化采购，以降低地缘政治和关税相关风险。这包括筛选合格的替代供应商，确保关键试剂的策略性库存缓衝，以及协商明确前置作业时间和支援的服务水准协议。第三，供应商和服务供应商应强调开放标准、通用资料格式和检验的API，以促进仪器、实验室资讯管理系统（LIMS）和分析平台之间的互通性，并降低最终用户的整合成本。

第四，商业团队应围绕以结果为导向的价值提案建构其产品，将仪器、检验的耗材和分析服务结合。对于转化倡议，公司应建立或与强大的临床检验途径、监管专业知识以及符合认证要求的可重复文件合作。最后，领导者应投资于人才培养——包括培训计画、方法学研讨会和应用支援——以帮助客户充分发挥转录组学技术的潜力，同时保持高标准的数据品质和检测可重复性。

结合相关人员访谈、技术基准化分析和情境分析的稳健混合方法研究设计，确保转录组学相关人员获得可复製和可操作的见解

本研究整合了来自相关人员、技术文献和已验证技术评估的原始信息，旨在对RNA分析和转录组学的发展趋势进行全面的、基于证据的分析。原始数据透过与实验室主任、采购专家和技术开发人员进行结构化访谈收集，并辅以供应商蓝图和同行评审的、记录检测性能和可重复性的方法学研究。二级资讯来源包括技术白皮书、监管指南文件以及说明工作流程效率和验证要求的基准研究。

此分析方法将相关人员访谈的定性主题编码与比较技术分析和基于场景的供应链分析相结合。关键效能属性，例如检测灵敏度、通量、工作流程复杂性和运算要求，被映射到不同产品和技术类别中，突出相容性限制和可行能力。在适当的情况下，我们运用案例和实际工作实务来说明研究机构如何进行平台选择和部署。在整个过程中，研究结果透过专家评审週期进行交叉检验，以确保技术准确性以及与研究和临床应用的实际相关性。

整合策略重点，强调转录组学中的技术能力、运作弹性和转化准备之间的相互作用

总而言之，RNA分析和转录组学正在从探索性科学转型为一个综合领域，技术选择、资料管理和供应链弹性共同决定研究和转化的成功。单细胞和高通量定序的进步正在释放新的生物学洞见，但它们的未来取决于严谨的工作流程、可互通的检测方法以及可靠的试剂和服务生态系统。对于寻求持续生产力的研究机构而言，跨多元化采购的营运弹性、清晰的供应商支援和检验的通讯协定与技术能力同等重要。

展望未来，那些将耗材、设备和分析方面的投资与可重复性和合规性相结合的相关人员，将最有能力将发现转化为实际影响。製造商、服务供应商和最终用户之间的合​​作将加速检验途径，并降低临床应用的门槛。最终，最成功的组织将是那些不仅将转录组学视为单一技术选择，而是将其视为一种系统级能力的组织，这种能力将整合实验室实践、计算严谨性和供应链规范，从而提供可靠、可操作的生物学见解。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 利用长读长RNA定序对全长异构体进行大规模分析
  • 整合成像和基因表现的空间转录组学技术快速发展
  • 扩展结合转录组分析和表观遗传学数据的单细胞多体学学分析
  • 实现人工智慧驱动的高通量转录组学数据解释分析平台
  • 直接 RNA定序方法的兴起，可以侦测天然转录本上的修饰
  • 开发用于可扩展单细胞转录组学研究的高密度微流体平台
  • 液态生物检体转录组学在微创癌症生物标记发现的进展
  • 标准化基于云端基础的管道，用于大型转录组学资料集的协作分析
  • 将 CRISPR筛检与转录组分析结合以识别功能基因标靶
  • 个人化肿瘤诊断对临床级转录组学检测的需求不断增长

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. RNA分析/转录组学市场（按产品）

  • 耗材和试剂
  • 装置
  • 软体和服务

9. RNA分析/转录组学市场（按技术）

  • 数位PCR
  • 微阵列
  • 次世代定序
    • 批量转录组学
    • 单细胞转录组学
      • 基于液滴
      • 基于微流体
  • 即时PCR

第 10 章 RNA 分析/转录组学市场（按应用）

  • 癌症研究
  • 药物研发
  • 基因检测
    • 携带者筛检
    • 疾病诊断
    • 产前和新生儿检测
  • 感染疾病监测
  • 植物调查

第 11 章 RNA 分析/转录组学市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 12 章：RNA 分析/转录组学市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 13 章 RNA 分析/转录组学市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • Roche Diagnostics International AG
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies Ltd.
    • Takara Bio Inc.
    • 10x Genomics, Inc.
Product Code: MRR-FB6C9E7932C7

The RNA Analysis/Transcriptomics Market is projected to grow by USD 13.46 billion at a CAGR of 10.79% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.92 billion
Estimated Year [2025] USD 6.57 billion
Forecast Year [2032] USD 13.46 billion
CAGR (%) 10.79%

A comprehensive primer on the scientific, operational, and translational forces reshaping RNA analysis and transcriptomics across research and clinical domains

The field of RNA analysis and transcriptomics is at a pivotal juncture, driven by advances in molecular biology, sequencing technologies, and computational analytics that together are redefining experimental and clinical approaches. Over the past several years, the community has moved beyond simple gene expression snapshots to adopt high-resolution, scalable methods that capture cellular heterogeneity, temporal dynamics, and regulatory complexity. As a result, research priorities have expanded from foundational discovery to translational applications that inform drug development, diagnostics, and precision agriculture. Consequently, institutions and commercial laboratories now prioritize integrated workflows that reduce time from sample to insight while increasing reproducibility and data interoperability.

Given these dynamics, laboratory leaders and strategic planners must balance investments across recurring consumables, capital instrumentation, and software-enabled analytics. Operational decisions increasingly hinge on the ability to harmonize wet-lab protocols with robust bioinformatics pipelines, including cloud-native solutions that support large-scale transcriptomics datasets. Moreover, stakeholder expectations have shifted: funders and regulators demand transparent validation, clinical partners need standardized assays, and publishing outlets require comprehensive metadata and reproducible pipelines. In sum, the RNA analysis landscape now rewards organizations that combine technological excellence with operational rigor, comprehensive data stewardship, and clear translational roadmaps that bridge discovery and application.

How converging high-throughput sequencing, single-cell innovations, and software-driven ecosystems are redefining operational priorities and commercial models in transcriptomics

The landscape of transcriptomics is undergoing transformative shifts that reflect both technological maturation and changing end-user requirements. Technologically, improvements in sequencing throughput and reductions in per-sample processing times have enabled broader adoption of single-cell approaches and high-content bulk studies, prompting laboratories to rethink experimental design toward deeper, more granular interrogation of biological systems. Concurrently, digital PCR and refined real-time PCR methods continue to provide rapid, high-sensitivity options for targeted assays, supporting diagnostics and validation workflows that require quantitative precision rather than genome-scale breadth.

Equally important is the convergence of laboratory automation, novel microfluidic platforms, and machine learning-driven analytics, which together permit higher throughput and more reproducible data generation. This integration is shifting value from standalone instruments to coupled ecosystems where consumables, instrument firmware, and analytical software are co-optimized. Business models are adapting in response: subscription and service-centric approaches for software and cloud analytics are becoming more prominent, while manufacturers emphasize validated end-to-end solutions for clinical and regulated environments. Additionally, as collaborative networks and multi-site studies grow, standards for data exchange, quality control, and assay validation are becoming more consequential, fostering an environment where interoperability and compliance are critical competitive differentiators.

Assessing the cumulative operational and strategic consequences of recent United States tariff actions on global procurement, supply resilience, and platform selection in transcriptomics

Recent trade policy developments and tariff actions in the United States have created a recalibration across global supply chains for laboratory equipment, reagents, and related components that support RNA analysis. Companies and institutions reliant on cross-border sourcing have experienced shifts in procurement strategies, prompting extended supplier qualification processes and increased emphasis on inventory resilience. Tariff-related cost pressures have incentivized manufacturers to evaluate alternative sourcing, localize certain production steps, and renegotiate supplier contracts to preserve margin and ensure continuity of supply.

Operationally, these changes have manifested as elongated lead times for specific instrument components and specialized reagents, with procurement teams instituting contingency inventories and diversified vendor lists to mitigate disruption. Research groups have adjusted procurement cadence and, in some cases, selected platforms with broader local service footprints to reduce exposure to import-related delays. From a product-development perspective, firms are accelerating design for manufacturability initiatives that reduce reliance on geopolitically sensitive parts and that enable modular sourcing across multiple regions.

Furthermore, the cumulative effect of tariff measures has driven strategic partnerships between suppliers and distributors to smooth customs compliance and to streamline logistics. These collaborations often include co-investment in regional warehousing, harmonized documentation processes, and expanded field service networks. For translational research and clinical assay deployment, the net impact includes a greater emphasis on supply-chain transparency, vendor management, and contractual safeguards that align procurement with operational risk tolerance. Looking forward, stakeholders are likely to continue prioritizing resilience and flexibility in sourcing decisions while monitoring policy shifts that could alter cross-border trade dynamics for critical laboratory inputs.

Deep segmentation analysis explaining how distinct product, technology, and application pathways create differentiated demand signals and R&D priorities across transcriptomics workflows

A granular segmentation perspective reveals differentiated demand drivers and adoption barriers across products, technologies, and applications in RNA analysis. When viewed by product type, recurring demand for consumables and reagents underpins laboratory continuity and represents a central operational priority for end users who require consistent lot-to-lot performance and supply reliability. Instruments remain a critical focal point for capital allocation decisions because platform selection dictates throughput, assay compatibility, and downstream data characteristics. Complementary software and services form the connective tissue that converts raw measurements into actionable knowledge, enabling standardization, regulatory compliance, and scalable analytics for multi-site studies.

By technology, the ecosystem includes digital PCR and real-time PCR as robust tools for targeted quantification and validation, while microarray technologies retain a niche for specific comparative expression studies. Next Generation Sequencing has emerged as the dominant high-resolution approach, with bulk transcriptomics serving broad discovery use cases and single cell transcriptomics enabling interrogation of heterogeneous tissues and rare cell types. Within single-cell studies, droplet-based methods provide high-throughput cell partitioning suitable for large-scale atlasing projects, whereas microfluidics-based platforms offer precise control for specialized assays and multiomic integrations. Each technological class carries distinct workflow implications: sample preparation requirements, computational needs, and quality control benchmarks vary and therefore influence adoption curves across organizations.

Application-driven segmentation further clarifies prioritization. Cancer research continues to demand deep transcriptomic profiling to elucidate tumor heterogeneity and therapeutic resistance mechanisms, while drug discovery leverages expression signatures and pathway analyses for target identification and pharmacodynamics. Genetic testing programs require robust, validated assays across carrier screening, disease diagnostics, and prenatal and newborn applications, with particular emphasis on assay sensitivity, specificity, and regulatory readiness. Infectious disease research relies on rapid, high-sensitivity assays and scalable sequencing to track pathogens and host responses, and plant research increasingly adopts transcriptomic tools to accelerate trait discovery and stress-response characterization. Understanding these intersecting segmentation axes helps organizations align product portfolios, R&D investments, and commercial strategies to the nuanced needs of each user community.

Regional dynamics and infrastructure realities that determine adoption pathways, partnership strategies, and regulatory alignment for transcriptomics across global geographies

Regional dynamics shape how transcriptomics tools and services are adopted, supported, and commercialized, reflecting differences in research funding, regulatory landscapes, industrial partnerships, and clinical infrastructure. In the Americas, a dense ecosystem of academic centers, biotech companies, and clinical laboratories drives early adoption of advanced sequencing platforms and single-cell technologies, with strong ties between translational research and commercial innovation. This environment fosters rapid technology validation, strategic collaborations, and a competitive service-provider sector that supports scaling from discovery to clinical-grade assays.

Across Europe, the Middle East, and Africa, adoption patterns are heterogeneous: leading research hubs and national initiatives accelerate uptake of high-throughput platforms and standardized workflows, while broader regional disparities reflect variable access to capital and laboratory infrastructure. Regulatory frameworks in some European jurisdictions place particular emphasis on clinical validation and data privacy, prompting suppliers to emphasize compliance and localized support. Meanwhile, collaborative consortia and pan-regional projects help disseminate best practices and enable resource-sharing for high-cost technologies.

In the Asia-Pacific region, expanding public and private investment in life sciences has elevated demand for both instruments and consumables. Several countries are developing strong domestic manufacturing and service capabilities, which influences procurement preferences and price sensitivity. Rapidly growing research communities and clinical genomics programs are driving adoption across pharmaceutical, agricultural, and public health domains. Taken together, these regional dynamics necessitate differentiated commercial strategies: multinational suppliers must tailor go-to-market approaches, service models, and partnerships to align with local regulatory requirements, infrastructure maturity, and customer support expectations.

Competitive behaviors, integration strategies, and capability priorities among solution providers that determine vendor selection and partnership opportunities in transcriptomics

Company activity across the RNA analysis and transcriptomics value chain reflects a blend of technological differentiation, service expansion, and strategic consolidation. Instrument manufacturers continue to compete on throughput, accuracy, and ease of use, while reagent suppliers focus on robust chemistry, lot consistency, and validated workflows that reduce assay variability. At the same time, analytics providers and software vendors are accelerating investments in cloud-native platforms, standardized pipelines, and interpretive layers that address both research and clinical reporting needs.

Strategic behaviors include targeted M&A to secure proprietary chemistries or analytics assets, partnership-based go-to-market approaches that bundle instruments with consumables and data services, and expanded field service networks to support global deployment. Companies that successfully integrate hardware, chemistry, and software often gain a competitive edge by reducing end-user validation burden and enabling faster time to insight. Conversely, specialist providers that focus on niche assay chemistries, microfluidic innovations, or advanced bioinformatics can capture value through collaborations with platform vendors and contract research organizations.

For customers, vendor selection now involves assessment of long-term support, interoperability, and the breadth of validated applications. Procurement decisions increasingly weigh roadmap transparency, regulatory readiness, and the availability of training and application support. The evolving competitive landscape favors organizations that can demonstrate demonstrable reproducibility, comprehensive validation datasets, and pragmatic pathways for clinical translation or industrial scale-up.

Actionable strategic imperatives for leaders to build resilient supply chains, interoperable ecosystems, and clinically translatable transcriptomics offerings

Industry leaders should adopt a proactive stance that emphasizes resilience, interoperability, and translational readiness across product and operational portfolios. First, organizational roadmaps must prioritize cross-functional alignment between wet-lab teams, bioinformatics units, and procurement to ensure that platform selections deliver both immediate experimental benefits and long-term scalability. Investment decisions should favor modular solutions that allow incremental expansion of capacity and that minimize lock-in to proprietary components without sacrificing validated performance.

Second, firms should double down on supply-chain transparency and diversified sourcing to mitigate geopolitical and tariff-related risks. This includes qualifying alternative suppliers, securing strategic inventory buffers for critical reagents, and negotiating service-level agreements that provide clarity on lead times and support. Third, vendors and service providers should emphasize open standards, common data formats, and validated APIs to facilitate interoperability across instruments, LIMS, and analytics platforms, reducing integration overhead for end users.

Fourth, commercial teams should structure offerings around outcome-focused value propositions that combine instrumentation, validated consumables, and analytics services. For translational initiatives, companies must build or partner for robust clinical validation pathways, regulatory expertise, and reproducible documentation that meet certification requirements. Finally, leaders should invest in workforce enablement-training programs, methodological workshops, and application support-to ensure that customers realize the full potential of transcriptomics technologies while maintaining high standards of data quality and assay reproducibility.

Robust mixed-methods research design combining stakeholder interviews, technical benchmarking, and scenario analyses to ensure reproducible and actionable insights for transcriptomics stakeholders

This research synthesized primary stakeholder input, technical literature, and validated technology assessments to produce a comprehensive, evidence-based analysis of RNA analysis and transcriptomics trends. Primary data were gathered through structured interviews with laboratory directors, procurement specialists, and technology developers, complemented by vendor roadmaps and peer-reviewed methodological studies that document assay performance and reproducibility. Secondary sources included technical white papers, regulatory guidance documents, and benchmarking studies that describe workflow efficiencies and validation requirements.

Analytical methods combined qualitative thematic coding of stakeholder interviews with comparative technology profiling and scenario-based supply-chain analysis. Key performance attributes-such as assay sensitivity, throughput, workflow complexity, and computational requirements-were mapped across product and technology segments to highlight compatibility constraints and enabling capabilities. Where appropriate, case examples and real-world operational practices were used to illustrate how institutions navigate platform selection and deployment. Throughout the process, findings were cross-validated via expert review cycles to ensure technical accuracy and practical relevance for both research and clinical audiences.

Synthesis of strategic priorities highlighting the interplay of technological capability, operational resilience, and translational readiness in transcriptomics

In conclusion, RNA analysis and transcriptomics are transitioning from exploratory science to an integrated field where technological selection, data stewardship, and supply-chain resilience jointly determine research and translational success. Advances in single-cell and high-throughput sequencing are unlocking new biological insights, yet their promise depends on rigorous workflows, interoperable analytics, and reliable reagent and service ecosystems. Operational resilience-spanning diversified sourcing, clear vendor support, and validated protocols-has become as important as technical capability for institutions seeking sustained productivity.

Looking ahead, stakeholders that align investments across consumables, instruments, and analytics while maintaining a focus on reproducibility and regulatory readiness will be best positioned to translate discovery into impact. Collaboration between manufacturers, service providers, and end users will accelerate validation pathways and lower barriers to clinical adoption. Ultimately, the most successful organizations will be those that treat transcriptomics not as a single technology choice but as a systems-level capability that integrates laboratory practice, computational rigor, and supply-chain discipline to deliver reliable, actionable biological insights.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of long-read RNA sequencing to resolve full-length transcript isoforms at scale
  • 5.2. Rapid growth of spatial transcriptomics techniques integrating imaging and gene expression
  • 5.3. Expansion of single-cell multiomics assays coupling transcriptome profiling with epigenetic data
  • 5.4. Implementation of AI-driven analytics platforms for high-throughput transcriptomic data interpretation
  • 5.5. Rise of direct RNA sequencing approaches enabling native transcript modifications detection
  • 5.6. Development of high-density microfluidic platforms for scalable single-cell transcriptomic studies
  • 5.7. Advancements in liquid biopsy transcriptomics for minimally invasive cancer biomarker discovery
  • 5.8. Standardization of cloud-based pipelines for collaborative analysis of large transcriptomics datasets
  • 5.9. Integration of CRISPR screening with transcriptome profiling for functional gene target identification
  • 5.10. Growing demand for clinical-grade transcriptomics assays in personalized oncology diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Analysis/Transcriptomics Market, by Product

  • 8.1. Consumables & Reagents
  • 8.2. Instruments
  • 8.3. Software & Services

9. RNA Analysis/Transcriptomics Market, by Technology

  • 9.1. Digital PCR
  • 9.2. Microarray
  • 9.3. Next Generation Sequencing
    • 9.3.1. Bulk Transcriptomics
    • 9.3.2. Single Cell Transcriptomics
      • 9.3.2.1. Droplet Based
      • 9.3.2.2. Microfluidics Based
  • 9.4. Real Time PCR

10. RNA Analysis/Transcriptomics Market, by Application

  • 10.1. Cancer Research
  • 10.2. Drug Discovery
  • 10.3. Genetic Testing
    • 10.3.1. Carrier Screening
    • 10.3.2. Disease Diagnostics
    • 10.3.3. Prenatal & Newborn Testing
  • 10.4. Infectious Disease Research
  • 10.5. Plant Research

11. RNA Analysis/Transcriptomics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. RNA Analysis/Transcriptomics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. RNA Analysis/Transcriptomics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Illumina, Inc.
    • 14.3.2. Thermo Fisher Scientific Inc.
    • 14.3.3. QIAGEN N.V.
    • 14.3.4. Agilent Technologies, Inc.
    • 14.3.5. Bio-Rad Laboratories, Inc.
    • 14.3.6. Roche Diagnostics International AG
    • 14.3.7. Pacific Biosciences of California, Inc.
    • 14.3.8. Oxford Nanopore Technologies Ltd.
    • 14.3.9. Takara Bio Inc.
    • 14.3.10. 10x Genomics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. RNA ANALYSIS/TRANSCRIPTOMICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. RNA ANALYSIS/TRANSCRIPTOMICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RNA ANALYSIS/TRANSCRIPTOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 264. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 265. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 268. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 269. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 270. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 271. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 274. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032